Back to top
more

Ventyx Biosciences (VTYX)

(Real Time Quote from BATS)

$2.15 USD

2.15
202,364

-0.09 (-4.02%)

Updated Aug 2, 2024 10:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VTYX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Ventyx Biosciences, Inc. [VTYX]

Reports for Purchase

Showing records 1 - 20 ( 22 total )

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

06/13/2024

Company Report

Pages: 5

Competitor NLRP3 Data Show Reduction in CRP, Though Significance Unknown

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

06/06/2024

Company Report

Pages: 5

VTX3232 Preclinical Obesity Data Provide POC Though a Combo Approach May be Needed

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

05/10/2024

Company Report

Pages: 6

1Q24 Recap: VTX3232 Obesity Mouse Data Expected in 2Q24; Phase 2a Trial Initiations on Track for 2H24

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

03/12/2024

Company Report

Pages: 4

NLRP3 Inhibitors Present Opportunities in Cardiovascular Diseases and Neuroinflammation; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

02/28/2024

Company Report

Pages: 7

4Q23 Recap; Several Clinical Data Updates to be Presented at Investor Event on March 11; PT Updated to $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

02/21/2024

Company Report

Pages: 5

Competitor Preclinical Publication of NLRP3 Inhibitors Demonstrates Potential Efficacy in Treating Obesity

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for VTYX 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/10/2023

Company Report

Pages: 5

3Q23 Recap: Several Pipeline Updates Expected in 1Q24; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

11/07/2023

Company Report

Pages: 5

VTX958 Thesis Does Not Pan Out

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

10/10/2023

Company Report

Pages: 5

Endoscopic Remission Is a Highlight in Positive Phase 2 VTX002 UC Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/11/2023

Company Report

Pages: 6

2Q23 Recap: Two Significant Catalysts Including Phase 2 UC and Psoriasis Data Expected in 4Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

07/05/2023

Company Report

Pages: 4

Best Oral Therapy for Psoriasis is Still Up for Grabs, in Our View

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/12/2023

Company Report

Pages: 7

1Q23 Recap: 2H23 Catalysts Include VTX002 UC Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/24/2023

Company Report

Pages: 5

4Q22 Take: All Timelines Remain on Track For an Eventful 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

03/20/2023

Company Report

Pages: 4

Our Views on TAK-279 Phase 2 Data and Read-Through to VTX958

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

01/27/2023

Company Report

Pages: 7

2023 is the Year of Execution With Initial Fruition Expected in 2H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

12/14/2022

Company Report

Pages: 4

Takeda Acquisition of Nimbus'' TYK2 Inhibitor Underscores That VTX958 is Undervalued

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/04/2022

Company Report

Pages: 5

3Q22 Take: Focus Is Now on Advancing the Pipeline Into Phase 2 Studies and VTX002 Top-Line Data in 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

09/29/2022

Company Report

Pages: 4

NLRP3 Deals Continue; We Believe Ventyx''s NLRP3s Are Overlooked Though Potentially Best-in-Class

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Ventyx Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

09/13/2022

Company Report

Pages: 6

No Black Box Warning For Sotyktu Could Increase the Market Potential of TYK2 Assets; Increasing PT to $50

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party
// eof